Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Hallmarks of primary headache: part 1 – migraine
Alberto Raggi, Matilde Leonardi, Marco A. Arruda, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 27
The preclinical discovery and development of atogepant for migraine prophylaxis
Carlo Baraldi, Dagmar Beier, Paolo Martelletti, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 7, pp. 783-788
Open Access | Times Cited: 10
Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 2, pp. 257-281
Open Access | Times Cited: 7
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2605-2614
Open Access | Times Cited: 7
Monoclonal Antibody Targeting CGRP Relieves Cisplatin-Induced Neuropathic Pain by Attenuating Neuroinflammation
Shun Xie, Zhenfang Gao, Jiale Zhang, et al.
Neurotoxicity Research (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 6
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Potential benefits and possible risks of CGRP-targeted multitherapy in migraine
Keiko Ihara, Tsubasa Takizawa, Narumi Watanabe, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 1-2, pp. 1-4
Open Access | Times Cited: 4
The role of nitric oxide and neuroendocrine system in pain generation
Aayush Gupta, Maja Vejapi, Nebojša Nick Knežević
Molecular and Cellular Endocrinology (2024) Vol. 591, pp. 112270-112270
Closed Access | Times Cited: 4
Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
William Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti
Expert Review of Neurotherapeutics (2024), pp. 1-11
Closed Access | Times Cited: 4
Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists
Marta Waliszewska‐Prosół, Bianca Raffaelli, Marcin Straburzyński, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 11, pp. 1039-1051
Closed Access | Times Cited: 4
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
A robust multimodal brain MRI-based diagnostic model for migraine: validation across different migraine phases and longitudinal follow-up data
Jong Young Namgung, Eunchan Noh, Yurim Jang, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
CGRPβ suppresses the pathogenesis of ulcerative colitis via the immunoproteasome
Tatsuya Shibao, Hiroaki Hase, Kodai Mizokami, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)
Katharina Kamm
Nervenheilkunde (2025) Vol. 43, Iss. 04, pp. 222-231
Closed Access
Migraine treatment with CGRP monoclonal antibodies: patient evaluation of a mandatory treatment holiday in Belgium
Ruben De Praeter, Elise Tuerlinckx, Jean Schoenen, et al.
Acta Neurologica Belgica (2025)
Closed Access
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment
Lanfranco Pellesi, Budour Jedie, Fadia Barhum, et al.
Pain Management (2025), pp. 1-6
Closed Access
Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics
Slobodan Јаnkovic, Snežana V. Janković
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 3, pp. 277-293
Closed Access | Times Cited: 2
Voltage-gated Calcium Channels as Potential Therapeutic Targets in Migraine
Juliana Geremias Chichorro, Eder Gambeta, Darciane Favero Baggio, et al.
Journal of Pain (2024) Vol. 25, Iss. 8, pp. 104514-104514
Closed Access | Times Cited: 2
An update on drug–drug interactions in older adults living with human immunodeficiency virus (HIV)
Rebecca Y. Linfield, Nancy N. Nguyen, Olivia H. Laprade, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 7, pp. 589-614
Closed Access | Times Cited: 1
Magnetoencephalography studies in migraine and headache disorders: A systematic review
Raghavan Gopalakrishnan, Nitesh Singh Malan, Nymisha Mandava, et al.
Headache The Journal of Head and Face Pain (2024)
Open Access | Times Cited: 1
Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro
Shirin R. Hasan, Dimitrios Manolis, Ewan Stephenson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Reducción de los niveles plasmáticos de CGRP en pacientes con migraña tratados con erenumab o galcanezumab
Daniel A. Garcı́a-Estévez, A. Juanatey-García, Jorge Rodríguez-Garrido, et al.
Revista de Neurología (2024) Vol. 78, Iss. 10, pp. 293-293
Closed Access
Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro
Shirin R. Hasan, Dimitrios Manolis, Ewan Stephenson, et al.
Cellular Signalling (2024) Vol. 121, pp. 111261-111261
Open Access
Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years
Eduardo Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 6, pp. 1317-1326
Closed Access
Page 1 - Next Page

Scroll to top